Navigation Links
Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association

ombination with other cancer therapies and in a number of cancer types are underway or planned.

About Pharmion

Pharmion is a biopharmaceutical company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic cancer drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit Pharmion's website at http://www.pharmion.com.

About GPC Biotech

GPC Biotech AG is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs. GPC Biotech's lead product candidate satraplatin is currently under review by the U.S. FDA for hormone-refractory prostate cancer patients whose prior chemotherapy has failed. GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany), and has a wholly owned U.S. subsidiary headquartered in Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at http://www.gpc-biotech.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech AG and Pharmion Corporation, including statements about the status of the FDA review process. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achie
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:8/22/2014)...  As the Medical Affairs, role has become more ... area are exploring methods to develop strong capabilities to ... at Best Practices, LLC is designed to give Medical ... key challenges they face. The consortium will provide a ... roundtable discussions where leaders discuss key findings from the ...
(Date:8/22/2014)... , Aug. 22, 2014  Dr. Mark ... with the Diamond Lifetime Achievement Award in the field ... CEO of Cardiovascular Clinical Associates. Dr. Rasak ... managing all major aspects of the business; overseeing the ... as primary coronary intervention. In addition, he is an ...
(Date:8/22/2014)... 22, 2014   Zacks Equity Research highlights Epizyme (Nasdaq: ... Day and Panera (Nasdaq: PNRA - Free Report ) as ... analysis on Amicus Therapeutics (Nasdaq: FOLD - Free Report ), ... SHPG - Free Report ). Here is a ... the Day : The biotech bull market is ...
Breaking Medicine Technology:Best Practices' Medical Affairs Consortium Survey Has Achieved Strong Participation 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6
... achieve undetectable viral load in Phase,IIa trial within ... care, SAN FRANCISCO, Nov. 1 New ... protease inhibitor (PI) being,developed by Tibotec BVBA for ... Tibotec will present findings from three TMC435 studies,including ...
... Higher Sustained Virological Response Rates Recognized as Marker ... 1 A new,independently-conducted study being presented at ... the Study of Liver Diseases (AASLD) shows that,PEGASYS(R) ... response (SVR) rates for hepatitis C patients as,compared ...
Cached Medicine Technology:Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 2Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 3Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 4Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7
(Date:8/22/2014)... Top 10 Best SEO Hosting (Top10BestSEOHosting.com) has ... highly recommended FatCow ( http://www.top10bestseohosting.com/go/FatCow.com/ ) and BlueHost ... 10 Best SEO Hosting states, “It is hard ... Actually, these companies have outperformed their competitors on ... People can get the best web hosting at ...
(Date:8/22/2014)... Buying a policy for different life insurance ... about available coverage types by insurers in the U.S. The ... pricing to the public using its sortable tool at ... free and is expected to promote the discounts and special ... the U.S. The system is designed to help an adult ...
(Date:8/22/2014)... 2014 Recently, iFitDress.com, a well-known wedding ... of discounted wedding gowns . In addition to ... these new products are provided with low shipping fees. ... to unveil the new wedding gowns. In our online ... for ladies to choose from. What’s more, all of ...
(Date:8/22/2014)... Health New Orleans School of Nursing was awarded ... increase access to advanced nursing education and patient ... well as veterans. The Health Resources and Services ... Human Services awarded the two-year grant. Scharalda Jeanfreau, ... director., The Advanced Education Nursing Traineeship (AENT) Program ...
(Date:8/22/2014)... Natural Clear Vision , a how-to guide ... vision from legally blind to perfect 20/20 vision has caught ... , “There is a huge portion of the population today ... most people just think that’s the way it will always ... be pretty risky at times,” reports Michaels. “This program is ...
Breaking Medicine News(10 mins):Health News:FatCow Reviews Released by Top10BestSEOHosting.com 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Discounted Wedding Gowns For Sale At Leading Online Shop iFitDress.com 2Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2
... Reporter , FRIDAY, March 18 (HealthDay News) -- ... U.S. Food and Drug Administration on Friday said that ... marketplace would benefit public health in the United States." ... that menthols, minty flavor may make smoking more attractive, ...
... , FRIDAY, March 18 (HealthDay News) -- Orthodontic retainers, removable ... of potentially harmful microbes if they aren,t properly cleaned, finds ... Institute checked the retainers of a group of study participants ... yeast called Candida that can cause fungal infections, ...
... . There,s nothing like the sheer delight of sun ... concentration can have nasty consequences. Taking a tumble on the slopes ... go by before knees regain their full function, and patients are ... the knee to heal is directly related to how well it ...
... Reporter , THURSDAY, March 17 (HealthDay News) -- A ... pimples, low self-esteem and depression often go hand-in-hand. ... problems, the analysis of 16 studies suggests that teenage ... "Acne has a huge impact on people,s lives," ...
... FRIDAY, March 18 (HealthDay News) -- Three of four ... not identified as victims of abuse, a new study ... of Medicine analyzed court, police and emergency department (ED) ... and 2002, and found that 80 percent of women ...
... to improve the conditions for immigrants to the EU through ... CPF will coordinate the Swedish contribution to a major EU ... health of migrants from North Africa. , "We are ... Swedish contribution to such a complex, exciting and important EU ...
Cached Medicine News:Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 2Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 3Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 4Health News:Orthodontic Retainers Can Harbor Harmful Microbes 2Health News:How to help heal an injured joint 2Health News:Acne May Blemish Teens' Emotional Lives, Too 2Health News:Domestic Abuse Often Escapes Notice of ER Staff: Study 2Health News:North African migrants' health and quality of life 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: